A brand new Alzheimer blood test, which was recently approved by the US Food and Drug Administration (FDA), can now recognize the disease in individuals with early stages of the disease. The research that led to knowledge was published within the Friday edition of Alzheimer’s and dementia: The Journal of the Alzheimer’s Association.
Highly
“Our study showed that blood tests confirmed the diagnosis of Alzheimer’s disease with a sensitivity of 95% and a specificity of 82%,” says the corresponded writer Gregg Day, MD Mayo Clinic neurologist, dementia specialist and clinical researcher.
In other words, 95% of the time recognized Alzheimer’s and excluded individuals who didn’t have dementia 82 percent of the time.
“Alzheimer’s disease affects too many people, more than breast cancer and prostate cancer,” said the FDA commissioner Martin A. Makary, MD, MPH “that 10% of people aged 65 and over will have Alzheimer’s and that will double this number by 2050.
The FDA quickly pursues the approval
The way in which blood is tested for Alzheimer’s disease is used by the use of the Lumipulse GP TAU217/B-amyloid plasma ratio. This measures the concentration of Ptau217, a dew protein that is involved in the brain. It also measures B-amyloid 1-42, which is a significant component of the amyloid plaque in the blood. The ratio of these proteins is measured against amyloid plaques in the brain to make a diagnosis.
The FDA solved the blood inspection Breakthrough. This means that its development, review and approval have been accelerated.
Cheaper and less invasive
Methods for diagnosing Alzheimer’s disease in the early stages were expensive and invasive.
Standard diagnostic measures usually begin with a review of family history as well as cognitive and functional studies. These steps are relatively inexpensive and not invasive. However, more detailed tests can include positron emission tomography (PET) or brain scans and spine taps.
The tests of the new Alzheimer’s are simply a blood development. There is no need to extract spine fluid or imaging.
“If this is completed within the outpatient clinical environment, this is analogous to the accuracy of the disease biomarkers of the cerebrospinal fluid and is far more convenient and price -effective,” said Day.
Cerebrospinal fluid biomarkers are proteins, peptides and nucleic acids that can uncover diseases, especially in the spine and brain.
How the study was carried out
Mayo’s study was carried out in his clinic in Jacksonville, Florida. Around 500 patients treated for memory disorders took part in research. They were 32 to 89 years old.
The results showed that 56% suffered from Alzheimer’s disease.
What causes Alzheimer’s disease
Alzheimer’s disease is an incurable brain disease. Usually it is slowly over several years. However, some people can move quickly.
Researchers try to determine what causes the development of protein deposits, mainly amyloid plaques and tau meals in the brain. However, It is known that other factors contribute to the development of Alzheimer’s diseaseAccording to the National Institute of Aging (NIA). This includes:
- Genetic aspects.
- Lifestyle – smoking, poor nutrition, lack of movement and pollution.
- Diseases – diabetes, high blood pressure and heart disease.
- Age – the disease usually develops according to 65.
- Brain injuries increase the risk of Alzheimer’s disease.
- Depression and social isolation.
- Obesity.
Most areas of the brain are ultimately affected by the disease. This includes memory, cognitive functions, language, problem solving, personality and exercise.
Five levels from Alzheimer’s
The Alzheimer disease generally moves through five stagesAccording to the Mayo clinic. The preclinical phase does not show any signs of the disease and is usually only found through tests. This phase can take years – even decades.
Symptoms such as minor memory loss and short-term thinking difficulties occur in the MIC stage of mild cognitive impairment (MIC). From there, the decline accelerates.
People live an average of 3 to 11 years after the diagnosis, reports the Mayo clinic. However, some have lived over 20 years. Life expectancy is influenced by how early a diagnosis is made, as well as the presence or lack of untreated vascular diseases such as high blood pressure.
Diagnosis – no healing
The new Alzheimer blood test is a milestone for researchers and patients. However, it is not a healing.
“Today is one other essential step within the diagnosis of Alzheimer’s disease,” said Maria C. Carrillo, Ph.D. when the test was approved by the FDA. It is the Chief Science Officer of the Alzheimer Association. “The Americans have too long problems to get an easy and precise diagnosis. With today’s FDA motion, we hope that it is simpler for more people to get a precise diagnosis earlier.”
Most individuals with Alzheimer’s disease experience Symptoms in the middle of the 1960s or lateraccording to the National Institute on. In very rare cases, signs of the disease can occur in people in the thirties.
Treatment
Early diagnosis is important for the quality of life of a patient, although there is currently no healing.
A Diversity of treatments Aim different facets of the disease.
Donanemabmarkets under the name Kisula and LecanemabPresent Marketed as a LeQembi, there are two treatments for early Alzheimer’s disease. They collect and remove both Beta-Amyloid from the brain.
While no remedies were shown, according to the Alzheimer Association, these treatments were shown that they reduced the progression of Alzheimer’s disease. However, there can be side effects, including amyloid -related imaging anomalies (Aria). This leads to a temporary swelling in areas of the brain.
When to see a doctor
June has been Alzheimer’s and Brain Awareness Month since 1983. This does this at the perfect time to concentrate on the health of the brain.
You should consider talking to a doctor if you or a loved one constantly have problems with memory, carry out routine tasks or think clearly.
The Alzheimer Association has created 10 early signs and symptoms of Alzheimer’s and dementia. This includes:
- Memory loss that disturbs daily life.
- Challenges in planning or solving problems.
- Difficulty to do familiar tasks.
- Confusion with time or place.
- Problems to understand visual pictures and spatial relationships.
- New problems with words when speaking or writing.
- Laying things and losing the ability to trace steps back.
- Reduced or bad judgment.
- Withdrawal from work or social activities.
- Changes in mood or personality.
Other sources of help
There are many resources available to help individuals and families deal with Alzheimer’s disease.
The Alzheimer Association contains the following links:
The Nia lists these resources:
Nia Alzheimer’s and related dementia education and transfer center (ATEAR) Center
800-438-4380
ateear@nia.nih.gov
www.nia.nih.gov/alzheimers
This center contains free information, including printing on Alzheimer’s and related dementia for families, supervisors and members of the health professions. The ADEAR Center employees answer telephone, e -mail and written inquiries and provide transfers to local and national resources.
Alzheimer.gov
www.alzheimers.gov
Information about Alzheimer’s and dementia is provided here by all federal authorities.
Eldercare Locator
800-677-1116
Eldercarelocator@usaging.org
https://eldercare.acl.gov
Medleplus
National Library for Medicine
www.medlineplus.gov
Alzheimer Association
800-272-3900
866-403-3073 (TTY)
info@alz.org
www.alz.org
Alzheimer’s Foundation of America
866-232-8484
info@alzfdn.org
www.alzfdn.org
Read more:
Max K. Erkilian began to write down for newspapers in the course of the highschool. He became an award -winning journalist and co -founder of Print Magazine Free Bird. He wrote for a big selection of regional and national publications in addition to for a lot of online publications. This gave him the chance to interview a lot of outstanding personalities by the previous chairman of the Federal Reserve Bank Paul Volker with the blues musicians Muddy Waters and BB King. Max lives in Springfield, Mo along with his wife Karen and her cat – pudge. He spends as much time as possible along with his children, grandchildren and great -grandchildren.
